In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MyoKardia, Inc.

http://www.myokardia.com

Latest From MyoKardia, Inc.

Earlier R&D Programs, Maturing Candidates Emerge From Bristol’s Pipeline

BMS is advancing a growing Phase I and II R&D pipeline, including a Factor XIa inhibitor with lower bleeding risk than current anticoagulants, as well as other internal and external research programs.

Strategy Cardiovascular

Bristol’s Bold Projections Grow Bolder As Confidence In R&D Programs Rises

Loss of exclusivity for key Bristol Myers Squibb products, starting with top seller Revlimid, is looming over the company’s R&D pipeline. BMS believes its late-stage and newly approved products will generate more than $25bn in sales by 2029.

Launches Strategy

LianBio Gets Chinese Biotech US IPOs Rolling Again But Followers Scant

Billed as BridgeBio in China, US-based and China-oriented biotech LianBio breaks a long hiatus in US listing for Chinese biotechs.

Financing China

BMS Focuses On Driving Future Growth As Revlimid Generic Launches Near

New product sales doubled from $161m in the first quarter to $344m in Q3 and the R&D pipeline advancing as planned ahead of generic competition for Revlimid, which will begin to launch in 2022.

Launches Sales & Earnings
See All

Company Information

  • Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
    • Drug Discovery Tools
      • ADMET
      • Genomics-Proteomics
UsernamePublicRestriction

Register